<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501527</url>
  </required_header>
  <id_info>
    <org_study_id>2006-001437-18</org_study_id>
    <secondary_id>6078-PG-OSL-145</secondary_id>
    <nct_id>NCT00501527</nct_id>
  </id_info>
  <brief_title>Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense</brief_title>
  <official_title>Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense in Patients Suffering From Allergic Rhinoconjunctivitis and/or Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Leti, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Leti, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate the clinical effectiveness of the administration
      of a depigmented and polymerized allergen extract of Phleum pratense in the
      rhinoconjunctivitis and/or asthma of slight or moderate intensity, due to allergy to grass
      pollen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunotherapy is a specific treatment for allergic diseases. Unlike conventional
      pharmacological treatment, immunotherapy is the only treatment that could modify the natural
      course of allergic disease. This is a prospective double-blind placebo controlled study with
      three arms of treatment: placebo and two active (one of the active arms will receive a dose
      that is 10x the dose of the other arm).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom scores</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal provocation test</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-response skin prick-test</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma quality of life questionnaire (AQLQ)/Rhinoconjunctivitis quality of life questionnaire (RQLQ)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication scores</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual scales</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;In vitro&quot; immunological tests</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record of adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <condition>Conjunctivitis, Allergic</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>A: Biological vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first active arm will receive a dose that is 10x less than the dose of the other arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: biological vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first active arm will receive a dose that is 10x more than the dose of the other arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunotherapy with modified extract of P. pratense pollen</intervention_name>
    <description>Sublingual (2 drops daily)</description>
    <arm_group_label>A: Biological vaccine</arm_group_label>
    <arm_group_label>B: biological vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2 drops daily</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive clinical history of allergy to Phleum pratense

          -  Patients of both gender aged from 12 up to 50 years.

          -  Positive prick test to Phleum pratense allergen extracts

          -  Specific IgE to Phleum pratense

          -  Positive clinical history of allergic rhinoconjunctivitis and/or asthma

          -  Written informed consent.

        Exclusion Criteria:

          -  Use of immunotherapy during the last four years.

          -  Any contraindication for the use of immunotherapy in accordance with European Allergy
             and Clinical Immunology Immunotherapy Subcommittee criteria:

          -  Treatment with ß-blockers

          -  Coexistence of immunopathological diseases (e.g. of the liver, kidney, the nervous
             system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role

          -  Patients suffering from immune deficiencies

          -  Patients with serious psychiatric / psychological disturbances

          -  In addition, the following was considered as exclusion criteria:

          -  Pregnant or/ in lactation patients

          -  Patients aspirin intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Félix Lorente, Prf. PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <last_update_submitted>December 16, 2010</last_update_submitted>
  <last_update_submitted_qc>December 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mª José Gómez</name_title>
    <organization>Laboratorios LETI S.L.Unipersonal</organization>
  </responsible_party>
  <keyword>Allergoid</keyword>
  <keyword>Depigmented</keyword>
  <keyword>Polymerized</keyword>
  <keyword>Allergen-extract</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

